Delving into the Latest Updates on Calcium Polystyrene Sulfonate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Calcium Polystyrene Sulfonate Powder, Calcium Polystyrene Sulphonate, Calcium Polystyrene Sulphonate Powder

+ [9]

Target

Muscle-type nAChRs

Action

agonists

Mechanism

Muscle-type nAChRs agonists(Muscle-type nicotinic acetylcholine receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hyperkalemia

Inactive Indication-

Originator Organization

Kowa Co., Ltd.

Active Organization

Beijing Peking University Pharmaceutical Co. Ltd.

Kowa Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (25 Apr 1975),

Hyperkalemia

Regulation-

Login to view timeline

This non-interventional, Phase IV, exploratory, cross-over, randomised, single-blind, active comparator-controlled study has been designed to measure the palatability and preference of Lokelma® versus Veltassa® versus S/CPS in patients with dialysis and non-dialysis chronic kidney disease (CKD) and hyperkalaemia (HK). The sponsor hypothesizes that palatability, in terms of taste, texture, smell, and mouthfeel, will score higher (better) for Lokelma when compared with Veltassa and S/CPS.

Start Date23 Oct 2020

Sponsor / Collaborator

AstraZeneca PLC

[+3]

ChiCTR1900020809

/ SuspendedPhase 1IIT

Evaluate the tolerance, safety, pharmacokinetic and pharmacodynamic of single dose in a single-center, randomized, double-blind and placebo-controlled phase?study of Lanthanum Polystyrene Sulphonate Powder.

Start Date23 Jan 2019

Sponsor / Collaborator

The First Hospital of Jilin University

ChiCTR-TTRCC-14004155

/ CompletedPhase 4IIT

Randomized crossover study of the efficacy and safety of Calcium polystyrene sulfonate in maintenance hemodialysis patients with dialysis hyperkalemia

Start Date01 Jan 2014

Sponsor / Collaborator

First Affiliated Hospital of Dalian Medical University

100 Clinical Results associated with Calcium Polystyrene Sulfonate

Login to view more data

100 Translational Medicine associated with Calcium Polystyrene Sulfonate

Login to view more data

100 Patents (Medical) associated with Calcium Polystyrene Sulfonate

Login to view more data

63

Literatures (Medical) associated with Calcium Polystyrene Sulfonate

31 Dec 2024·Renal Failure

Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K)

Article

Author: Chen, Qinkai ; Shi, Yifan ; Zuo, Li ; Yao, Li ; Luo, Qun ; Ni, Zhaohui ; Zhang, Xinzhou ; Qin, Shuguang ; Jin, Haijiao ; Peng, Hui ; Xiao, Jie ; Ren, Yuqing ; Lu, Renhua ; Yu, Weimin ; Shao, Guojian ; Zhang, Lihong ; Yang, Qiongqiong ; Zhang, Qinghong

OBJECTIVESPatients with end-stage renal disease (ESRD) on hemodialysis (HD) are at risk for hyperkalemia (HK), associated with cardiac arrhythmia and sudden death. Data on the burden of HK and management techniques among HD patients in China are still scarce. This study assessed the treatment modalities, recurrence, and prevalence of HK in Chinese HD patients.METHODSIn this prospective cohort study conducted from May 2021 to July 2022, patients aged ≥18 years who had ESRD and were on HD were enrolled from 15 centers in China (up to 6 months).RESULTSOverall, 600 patients were enrolled. At the baseline visit, mean (± standard deviation) urea reduction ratio was 68.0% ± 9.70 and Kt/V was 1.45 ± 0.496. Over 6 months, 453 (75.5%) patients experienced HK, of whom 356 (78.6%) recurred. Within 1, 2, 3, 4, 5, and 6 months, 203 (44.8%), 262 (57.8%), 300 (66.2%), 326 (72.0%), 347 (76.6%), and 356 (78.6%) patients had at least one HK recurrence event, respectively. The proportions of patients with ≥1, 2, 3, 4, 5, or 6 HK recurrence events were 356 (78.6%), 306 (67.5%), 250 (55.2%), 208 (45.9%), 161 (35.5%), and 110 (24.3%), respectively. Among the 453 patients who experienced HK, only 24 (5.3%) were treated with potassium binders: seven (1.5%) with sodium polystyrene sulfonate, 13 (2.9%) with calcium polystyrene sulfonate, and six (1.3%) with sodium zirconium cyclosilicate.CONCLUSIONSince HK is a chronic illness, long-term care is necessary. Patients on HD should have effective potassium management on non-dialysis days, yet our real-world population rarely used potassium binders.TRIAL REGISTRATIONClinicalTrials.gov Identifier NCT04799067.

01 Oct 2024·Clinical Nephrology

Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis

Article

Author: Fu, Xiaojuan ; Zhang, Sen ; Gao, Fang ; Mao, Nan

BACKGROUNDHyperkalemia is a common complication of chronic kidney disease (CKD). This study aims to investigate the efficacy and safety of sodium zirconium cyclosilicate and calcium polystyrene sulfonate in reducing potassium in patients with acute and severe hyperkalemia in CKD who are not undergoing dialysis.MATERIALS AND METHODSA retrospective real-world study was conducted among 73 patients with non-dialysis chronic kidney disease who were hospitalized in the First Affiliated Hospital of Chengdu Medical College from June 2020 to June 2022. 33 patients treated with sodium zirconium cyclosilicate were categorized as SZC group, and the other 40 patients treated with calcium polystyrene sulfonate were categorized as CPS group. Serum potassium, serum sodium, magnesium, calcium, and phosphorus levels were examined. Adverse reactions were recorded during medication.RESULTSSignificantly decreased serum potassium was observed in both groups, whereas the potassium reduction was higher in the SZC group than in the CPS group at 2, 4, 24, and 48 hours after medication while there was no statistically significant difference in the serum potassium level between the two groups at 72 hours. For those people whose initial potassium exceeded 6 mmol/L, the potassium reduction was more obvious in the SZC group than in the CPS group at 2 and 4 hours after medication. The control rate of hyperkalemia in the SZC group was significantly higher than in the CPS group at 4, 24, and 48 hours. No distinct change was observed in serum sodium, calcium, magnesium, and phosphorus before and 72 hours after medication. No severe adverse reactions occurred.CONCLUSIONSodium zirconium cyclosilicate has a more obvious effect on reducing potassium particularly for those patients with moderate to severe hyperkalemia who need rapid potassium reduction.

01 Oct 2024·Cureus

Comparison of Sodium Zirconium Cyclosilicate to Calcium Polystyrene Sulfonate for Acute Hyperkalemia Among Hospitalized Elderly Patients.

Article

Author: Kurihara, Tomohiro ; Yoshihara, Satsuki ; Komagamine, Junpei

Background Our aim was to investigate the effect of sodium zirconium cyclosilicate (SZC) on acute hyperkalemia in hospitalized elderly patients. Methods A retrospective observational study was conducted. All consecutive patients aged 65 years or older who were hospitalized in our hospital between January 2020 and September 2023 were screened. Patients with serum potassium greater than 5.0 mEq/L and those who were prescribed either SZC or calcium polystyrene sulfonate (CPS) during hospitalization were included. The primary outcome was the change in serum potassium within 24 hours from baseline. Patients who were prescribed SZC and those who were prescribed CPS were compared by the Mann-Whitney test. Results A total of 87 hospitalized elderly patients with acute hyperkalemia were included. The median age of the patients was 81 years (IQR 75 to 86); 64 (73.6%) were men, and 64 (73.6%) had chronic kidney disease. The median serum potassium concentration was 6.0 mEq/L (IQR 5.7 to 6.4). Of those, 53 patients received SZC, and 35 patients received CPS. While SZC reduced the serum potassium concentration from 6.1 mEq/L to 5.0 mEq/L, CPS reduced the potassium concentration from 5.9 mEq/L to 5.3 mEq/L within 24 hours. Compared with CPS, SZC significantly reduced potassium (p = 0.003). Conclusions Compared with CPS, SZC might reduce serum potassium more among hospitalized elderly patients with hyperkalemia. Further studies are warranted to determine the role of SZC for acute hyperkalemia in acute care settings.

100 Deals associated with Calcium Polystyrene Sulfonate

Login to view more data